Shares of Axsome Therapeutics were up after the company announced positive long-term results from a Phase III major depressive disorder (MDD) study that sets up potential regulatory approval for AXS-05.
https://www.pharmalive.com/wp-content/uploads/2020/12/Hope-Shines-Through-as-Axsome-Seeks-Approval-for-MDD-Drug-BioSpace-12-1-20.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2020-12-01 14:58:462020-12-02 15:08:25Axsome Seeks Approval for MDD Drug